Back to results
US 2023/0146253 A1Published application
Methods related to bronchial premalignant lesion severity and progression
AssigneesTrustees of Boston University, Health Research, Inc.
InventorsJennifer E. Beane-Ebel, Avrum E. Spira, Marc Lenburg, Mary E. Reid, Sarah Mazzilli
Life of this patent
Estimating the term…
Abstract
The technology described herein is directed to methods of treating and diagnosing bronchial premalignant lesions, e.g. by determining the lesion subtype using one or more biomarkers described herein.
Claims21
A method comprising measuring the level of expression of at least one module 9 gene in a sample obtained from a subject, wherein the at least one module 9 gene is selected from the group consisting of:
- LAP3;
- NUB1;
- CD74;
- BTN3A1;
- EIF2AK2;
- PARP12;
- SP100;
- IFI35;
- LAG3;
- PSME1;
- APOL4;
- APOL1;
- PSME2;
- TRIM14;
- DDX58;
- OAS3;
- OAS2;
- BTN3A3;
- BTN2A1;
- XRN1;
- IFIH1;
- STAT1;
- GBP1;
- IFIT3;
- TNFSF10;
- OPTN;
- NMI;
- ZNFX1;
- RNF114;
- BTN2A2;
- IRF1;
- IFI6;
- APOL3;
- APOL2;
- BST2;
- KLHDC7B;
- HELZ2;
- IDO1;
- TRIM21;
- TRIM22;
- EPSTI1;
- CMPK2;
- TRAFD1;
- TOR1B;
- DDX60;
- IFI44L;
- IFI44;
- PARP9;
- HERC6;
- CXCL9;
- WARS;
- PML;
- NLRC5;
- IFIT5;
- UBE2L6;
- MX1;
- USF1;
- ADAR;
- LY6E;
- GBP4;
- DTX3L;
- IL15;
- IFI27;
- C2;
- B2M;
- BATF2;
- TAP1;
- LGALS9;
- CXCL10;
- PARP14;
- RNF213;
- SAMD9L;
- HLA-DQB1;
- CIITA;
- SOCS1;
- SP140L;
- TRIM69;
- BTN3A2;
- ISG15;
- RUFY4;
- PLSCR1;
- HLA-DRB1;
- HLA-DQA1;
- ACSL5;
- C5orf56;
- HLA-DOA;
- HLA-DMA;
- TAPSAR1;
- PSMB8;
- HLA-DRA;
- HLA-C;
- HLA-E;
- HLA-F;
- PSMB10;
- EXOC3L4;
- HCP5;
- HLA-A;
- UBD;
- IRF9;
- APOL6;
- HLA-DPB1;
- PSME2P2;
- GBP1P1;
- HLA-DPA1;
- TAPBP;
- HLA-DQB2;
- HLA-B;
- OR2I1P;
- PSMB9;
- and HLA-DMB.
107 more elements
Dependencies are inferred from the claim text.